ANTHRACYCLINE-INDUCED CARDIAC TOXICITY
Clinical trials for ANTHRACYCLINE-INDUCED CARDIAC TOXICITY explained in plain language.
Never miss a new study
Get alerted when new ANTHRACYCLINE-INDUCED CARDIAC TOXICITY trials appear
Sign up with your email to follow new studies for ANTHRACYCLINE-INDUCED CARDIAC TOXICITY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Arm cuff trial aims to shield hearts from chemo damage
Disease control Recruiting nowThis study is testing whether a simple, non-invasive procedure called remote ischemic conditioning can protect the heart in lymphoma patients receiving a common but potentially heart-damaging chemotherapy. Over 600 patients at risk for heart problems will be randomly assigned to …
Matched conditions: ANTHRACYCLINE-INDUCED CARDIAC TOXICITY
Phase: NA • Sponsor: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Heart-Saving pill may shield cancer patients from chemo damage
Prevention Recruiting nowThis study is testing whether a drug called dapagliflozin can protect the heart from damage caused by a common type of breast cancer chemotherapy. About 100 women receiving anthracycline chemotherapy will take either dapagliflozin or a placebo pill daily during treatment. Researc…
Matched conditions: ANTHRACYCLINE-INDUCED CARDIAC TOXICITY
Phase: PHASE2 • Sponsor: University Medical Centre Ljubljana • Aim: Prevention
Last updated Apr 01, 2026 19:56 UTC